When Alector originally completed its initial public offering, it did not offer a dividend yield, adhering to standard practices for early-stage biotechnology enterprises. Clinical-stage biopharmaceutical firms typically do not distribute dividends because they reinvest all capital into research and development, clinical trials, and pipeline expansion. Consequently, the expected dividend yield upon its market launch was zero, as investors purchase shares purely for potential capital appreciation rather than income generation.